Asher Schranz is an Infectious Disease physician affiliated with University of North Carolina at Chapel Hill. OpenAlex indexes 69 publications with 1,323 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Eastowne Dr
Chapel Hill, NC 275142286
Telephone
984-974-7198Provider last certified this registry record 18 Nov 2021.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
88.2%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor25.8%Isentress54%Tivicay46%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor24.7%Triumeq52%Descovy48%Part D<11 patients+ 2 more classes in this area
Cardiovascular
11.8%Statin11.8%Atorvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Drug-use associated infective endocarditis: Post-hospitalization outcomes and patient treatment preferences
Univ of North Carolina Chapel Hill
FY2024$176,065K23DA049946 - Drug-use associated infective endocarditis: Post-hospitalization outcomes and patient treatment preferences
Univ of North Carolina Chapel Hill
FY2023$176,065K23DA049946 - Drug-use associated infective endocarditis: Post-hospitalization outcomes and patient treatment preferences
Univ of North Carolina Chapel Hill
FY2022$176,065K23DA049946
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Emergence of Infective Endocarditis Due to <i>Serratia</i> spp.: Results of a Multicenter Cohort
Open Forum Infectious Diseases
2025 - Patients’ Perspectives on Alternative Antibiotic Treatment Strategies for Infective Endocarditis Among Persons Who Inject Drugs
Journal of Addiction Medicine
2025 - Strategies to Improve Patient-Centered Care for Drug Use-Associated Infective Endocarditis
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Robert Sandler, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Hyman Muss, MD
University of North Carolina at Chapel Hill
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”